nach oben

Erschienen in:

01.02.2013 | Original Article

Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion

verfasst von: Kazuhiro Kitamura, Kaoru Kubota, Masahiro Ando, Satoshi Takahashi, Nobuhiko Nishijima, Teppei Sugano, Masaru Toyokawa, Koji Miwa, Seiji Kosaihira, Rintaro Noro, Yuji Minegishi, Masahiro Seike, Akinobu Yoshimura, Akihiko Gemma

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The presence of malignant pleural effusion (MPE) indicates a poorer prognosis for patients with non-small-cell lung cancer (NSCLC) and impairs their quality of life. Because vascular endothelial growth factor (VEGF) is the key mediator MPE production, we evaluated the efficacy and safety of chemotherapy plus bevacizumab, an anti-VEGF antibody, in non-squamous NSCLC patients with MPE, especially regarding the control of pleural effusions.

Methods

From November 1, 2009 to September 30, 2011, medical charts of 13 consecutive patients with MPE who received bevacizumab plus chemotherapy as the initial or secondary treatment were retrospectively analyzed.

Results

Of the 13 patients, 6 did not undergo pleurodesis, 3 were unsuccessfully treated by pleurodesis, 2 had encapsulated pleural effusion, and 2 had no re-expansion of the lung. Twelve patients (92.3 %) achieved MPE control lasting >8 weeks following bevacizumab plus chemotherapy. Five of 10 patients with measurable lesions had confirmed partial responses. Of 3 patients without measurable lesions, one had confirmed CR. Median progression-free survival time without re-accumulation of MPE was 312 days. Grade 3 or 4 neutropenia, thrombocytopenia, hypertension, or proteinuria was observed in 2, 2, 1, or 1 patient, respectively.

Conclusions

This is the first study to report that bevacizumab plus chemotherapy is highly effective for the management of MPE in non-squamous NSCLC patients. Prospective clinical trials are warranted to investigate the efficacy of bevacizumab for MPE.

Figlin R, Mendoza E, Piantadosi S et al (1994) Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861. Chest 106:S363–S366

Sugiura S, Ando Y, Minami H et al (1997) Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 3:47–50PubMed

Goodman A, Davies CW (2006) Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: a randomized trial. Lung Cancer 54:51–55PubMedCrossRef

Stefani A, Natali P, Casali C et al (2006) Talc poudrage versus talc slurry in the treatment of malignant effusion. A prospective comparative study. Eur J Cardiothorac Surg 30:827–832PubMedCrossRef

Kolscmann S, Ballin A, Gillissen A (2005) Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest 128:1431–1435CrossRef

Dresler CM, Olack J, Herndon JE II et al (2005) Phaze III intergroup study of talc poudrage versus talc slurry sclerosis for malignant pleural effusion. Chest 127:909–915PubMedCrossRef

da Silveira Paschoalini M, Vargas FS, Marchi E et al (2005) Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions. Chest 128:684–689CrossRef

Sartori S, Tassinari D, Ceccotti P et al (2004) Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound guided small-bore chest tube in the palliative treatment of malignant pleural effusions. J Clin Oncol 22:1228–1233PubMedCrossRef

Yoshida K, Sugiura T, Takifuji N et al (2007) Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515. Lung Cancer 58:362–368PubMedCrossRef

10.

Ishimoto O, Saijo Y, Narumi K et al (2002) High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology 63(1):70–75PubMedCrossRef

11.

Ruiz E, Almán C, Alegre J et al (2005) Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions. Lung 183:185–195PubMedCrossRef

12.

Hamed EA, El-Noweihi AM, Mohamed A et al (2004) Vasoactive mediators (VEGF and TNF-α) in patients with malignant and tuberculous effusions. Respirology 9:81–86PubMedCrossRef

13.

Thickett DR, Armstrong L, Millar AB et al (1999) Vascular endothelial growth factor (VEGF) inflammatory and malignant pleural effusions. Thorax 54:707–710PubMedCrossRef

14.

Grove CS, Lee YC (2002) Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 8:294–301PubMedCrossRef

15.

Brown LF, Detmar M, Claffy K et al (1997) Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 79:233–269PubMed

16.

Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368–4380PubMedCrossRef

17.

Cheng DS, Lee YC, Rodgers JT et al (2000) Vascular endothelial growth factor level correlates with transforming growth factor beta isoform levels in pleural effusions. Chest 118:1747–1753PubMedCrossRef

18.

Cheng DS, Rodriguez RM, Perkett EA et al (1999) Vascular endothelial growth factor in pleural fluid. Chest 116:760–765PubMedCrossRef

19.

Yanagawa H, Takeuchi E, Suzuki Y et al (1999) Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother 48:396–400PubMedCrossRef

20.

Verheul HMW, Hoekman K, Jorna AS et al (2000) Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 5:45–50PubMedCrossRef

21.

Strizzi L, Catalano A, Vianale G et al (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193:468–475PubMedCrossRef

22.

Rebeiro CCS, Vargas FS, Antonangelo L et al (2009) Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion. Respirology 14:1188–1193CrossRef

23.

Luo JC, Toyoda M, Shibuya M (1998) Different inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody. Cancer Res 58:2594–2600PubMed

24.

Shibuya M, Luo JC, Toyoda M et al (1999) Involvement of VEGF and its receptors in ascites tumor formation. Cancer Chemother Pharmacol 43(suppl):S72–S77PubMedCrossRef

25.

Hu L, Hoffmann J, Zaloudek C et al (2002) Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 161:1917–1924PubMedCrossRef

26.

Mesiano S, Ferrara N, Jaffe RB et al (1998) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153:1249–1256PubMedCrossRef

27.

Shaheen RM, Ahmad SA, Liu W et al (2001) Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 85:584–589PubMedCrossRef

28.

Pichelmayer O, Gruenberger B, Zielinski C et al (2006) Bevacizumab is active in malignant effusion. Ann Oncol 17:1853PubMedCrossRef

29.

Numnun TM, Rocconi RP, Whitworth J et al (2006) The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 102:425–428CrossRef

30.

El-Shami K, Elsaid A, El-kerm Y (2007) Open-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascites. J Clin Oncol 205(18 suppl):9043

31.

Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumzb for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRef

32.

Reck M, von Pawl J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227–1234PubMedCrossRef

33.

Reck M, von Pawl J, Zatloukal P et al (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first line therapy for nonsquamous non-small-cell lung cancer: results from a randomized phase III trial (AVAiL). Ann Oncol 21:1804–1809PubMedCrossRef

Titel: Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion
verfasst von: Kazuhiro Kitamura
Kaoru Kubota
Masahiro Ando
Satoshi Takahashi
Nobuhiko Nishijima
Teppei Sugano
Masaru Toyokawa
Koji Miwa
Seiji Kosaihira
Rintaro Noro
Yuji Minegishi
Masahiro Seike
Akinobu Yoshimura
Akihiko Gemma
Publikationsdatum: 01.02.2013
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 2/2013
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-012-2026-4

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion